Therapeutics that leverage protein degradation as their primary mechanism of action appear to be a validated new therapeutic modality. The current clinical molecules are focused on degrading ...

As gene therapies continue to advance, the demand for scalable, reproducible, and efficient potency assays is rapidly increasing—especially for adeno-associated virus (AAV) vectors. Accurate ...

Join Alamar Biosciences for an expert-led webinar exploring how emerging proteomics technologies—like NULISAseq™ high-sensitivity, multiplexed assays—are enabling more precise, scalable, and ...

Protein biomarker assays will remain the largest segment. The global digital immunoassays market is set to expand at a ...